Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review
RE Barth, MFS van der Loeff, R Schuurman… - The Lancet infectious …, 2010 - thelancet.com
Following large-scale roll-out of antiretroviral therapy in sub-Saharan Africa, the non-clinical
efficacy of antiretroviral therapy has received little attention. We aimed to systematically …
efficacy of antiretroviral therapy has received little attention. We aimed to systematically …
[PDF][PDF] Update on HIV-1 diversity in Africa: a decade in review
RW Lihana, D Ssemwanga, A Abimiku, N Ndembi - Aids Rev, 2012 - researchgate.net
Background: HIV-1 strains have diversified extensively through mutation and recombination
since their initial transmission to human beings many decades ago in Central Africa in the …
since their initial transmission to human beings many decades ago in Central Africa in the …
[PDF][PDF] Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world
D Frentz, CA Boucher, DA Van De Vijver - AIDs Rev, 2012 - academia.edu
A substantial number of studies have been performed across the world to determine
transmitted drug resistance. Large variations between different parts of the world can be …
transmitted drug resistance. Large variations between different parts of the world can be …
Genetic diversity of HIV in Africa: impact on diagnosis, treatment, vaccine development and trials
M Peeters, C Toure-Kane, JN Nkengasong - Aids, 2003 - journals.lww.com
AIDS is caused by two lentiviruses: HIV-1 and HIV-2 [1, 2]. AIDS was first recognized in the
1980s and is presently the leading cause of death in developing countries. Globally, it is …
1980s and is presently the leading cause of death in developing countries. Globally, it is …
Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre …
C Laurent, C Kouanfack, S Koulla-Shiro, N Nkoué… - The Lancet, 2004 - thelancet.com
Background Generic fixed-dose combinations have been prequalified by WHO to treat HIV-
infected patients in resource-limited countries. Despite their widespread use they are …
infected patients in resource-limited countries. Despite their widespread use they are …
Long-term benefits of highly active antiretroviral therapy in Senegalese HIV-1-infected adults
C Laurent, NFN Gueye, CT Ndour… - JAIDS Journal of …, 2005 - journals.lww.com
Objectives: To assess the long-term survival, as well as the immunologic and virologic
effectiveness, adherence, and drug resistance, in HIV-infected patients receiving highly …
effectiveness, adherence, and drug resistance, in HIV-infected patients receiving highly …
Association between medication possession ratio, virologic failure and drug resistance in HIV-1–infected adults on antiretroviral therapy in Côte d'Ivoire
E Messou, ML Chaix, D Gabillard, A Minga… - JAIDS Journal of …, 2011 - journals.lww.com
Background: Adherence is a strong determinant of viral suppression with antiretroviral
therapy (ART) but measuring it is challenging. Medication delivery can be measured …
therapy (ART) but measuring it is challenging. Medication delivery can be measured …
Emergence of multiclass drug–resistance in HIV-2 in antiretroviral-treated individuals in senegal: implications for hiv-2 treatment in resouce-limited West Africa
GS Gottlieb, NMD Badiane, SE Hawes… - Clinical Infectious …, 2009 - academic.oup.com
Background. The efficacy of various antiretroviral (ARV) therapy regimens for human
immunodeficiency virus type 2 (HIV-2) infection remains unclear. HIV-2 is intrinsically …
immunodeficiency virus type 2 (HIV-2) infection remains unclear. HIV-2 is intrinsically …
[HTML][HTML] Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996–2008)
JL Martinez-Cajas, NP Pai, MB Klein… - Journal of the …, 2009 - Springer
Ninety percent of HIV-1-infected people worldwide harbour non-subtype B variants of HIV-1.
Yet knowledge of resistance mutations in non-B HIV-1 and their clinical relevance is limited …
Yet knowledge of resistance mutations in non-B HIV-1 and their clinical relevance is limited …
[HTML][HTML] Prevention and treatment of human immunodeficiency virus/acquired immunodeficiency syndrome in resource-limited settings
DR Hogan, JA Salomon - Bulletin of the World Health …, 2005 - SciELO Public Health
Strategies for confronting the epidemic of human immunodeficiency virus/acquired
immunodeficiency syndrome (HIV/AIDS) have included a range of different approaches that …
immunodeficiency syndrome (HIV/AIDS) have included a range of different approaches that …